at Investor's Business Daily (Tue, 11:57AM)
Shares of Bristol-Myers (BMY -0.7%) slide after a federal judge rules a U.S. patent for its hepatitis B treatment Baraclude is invalid, saying there's clear and convincing evidence that a key claim in the patent is invalid due to obviousness. The ruling opens the door to Teva Pharmaceutical (TEVA +0.4%) selling a competing generic copy. BMY says it's disappointed in the ruling and plans to appeal.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Tue, 8:44AM)
at CNBC.com (Jan 20, 2015)
at CNBC.com (Jan 15, 2015)
at Benzinga.com (Jan 15, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs